Newamsterdam Pharma Stock Performance

NAMSW Stock   25.97  2.79  12.04%   
The company secures a Beta (Market Risk) of -1.36, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning NewAmsterdam Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, NewAmsterdam Pharma is expected to outperform it. At this point, NewAmsterdam Pharma has a negative expected return of -0.0938%. Please make sure to verify NewAmsterdam Pharma's sortino ratio, semi variance, as well as the relationship between the Semi Variance and day median price , to decide if NewAmsterdam Pharma performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days NewAmsterdam Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, NewAmsterdam Pharma is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more

Actual Historical Performance (%)

Five Day Return
(0.12)
Year To Date Return
12.42
Ten Year Return
918.43
All Time Return
918.43
Last Split Factor
1:1
Last Split Date
2022-11-23
1
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansion - July 2025 Macro Moves Entry and Exit Point Strategies - Newser
12/04/2025
2
Disposition of 75117 shares by Louise Kooij of NewAmsterdam Pharma at 36.21 subject to Rule 16b-3
12/23/2025
3
Disposition of 43872 shares by Louise Kooij of NewAmsterdam Pharma at 35.3 subject to Rule 16b-3
12/26/2025
4
Wells Fargo Maintains NewAmsterdam Pharma With Buy Rating, Maintains Target Price 45 -
01/08/2026
5
Disposition of 11582 shares by Davidson Michael H. of NewAmsterdam Pharma subject to Rule 16b-3
01/09/2026
6
Analysts Have Conflicting Sentiments on These Healthcare Companies Bicara Therapeutics Inc. , NewAmsterdam Pharma Company and GE Healthcare Technologies Inc - T...
01/15/2026
7
Disposition of 19604 shares by Mayur Somaiya of NewAmsterdam Pharma at 32.38 subject to Rule 16b-3
01/20/2026
8
Disposition of 60216 shares by Mayur Somaiya of NewAmsterdam Pharma at 9.26 subject to Rule 16b-3
01/22/2026
9
Disposition of 309 shares by Louise Kooij of NewAmsterdam Pharma at 33.45 subject to Rule 16b-3
01/26/2026
10
Disposition of 816 shares by Louise Kooij of NewAmsterdam Pharma at 32.62 subject to Rule 16b-3
01/27/2026
11
A Look At NewAmsterdam Pharma Valuation After Positive Obicetrapib Phase 3 Data And Regulatory Updates - simplywall.st
01/30/2026
12
NewAmsterdam Expands Obicetrapib Trials Into Diabetes And Alzheimers As Losses Mount - simplywall.st
02/18/2026
13
Disposition of 26011 shares by Louise Kooij of NewAmsterdam Pharma at 35.68 subject to Rule 16b-3
02/20/2026
Begin Period Cash Flow771.7 M
Total Cashflows From Investing Activities-174.9 M

NewAmsterdam Pharma Relative Risk vs. Return Landscape

If you would invest  2,997  in NewAmsterdam Pharma on November 26, 2025 and sell it today you would lose (400.00) from holding NewAmsterdam Pharma or give up 13.35% of portfolio value over 90 days. NewAmsterdam Pharma is currently producing negative expected returns and takes up 5.4419% volatility of returns over 90 trading days. Put another way, 48% of traded stocks are less volatile than NewAmsterdam, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon NewAmsterdam Pharma is expected to under-perform the market. In addition to that, the company is 7.14 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

NewAmsterdam Pharma Target Price Odds to finish over Current Price

The tendency of NewAmsterdam Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 25.97 90 days 25.97 
about 23.78
Based on a normal probability distribution, the odds of NewAmsterdam Pharma to move above the current price in 90 days from now is about 23.78 (This NewAmsterdam Pharma probability density function shows the probability of NewAmsterdam Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon NewAmsterdam Pharma has a beta of -1.36. This indicates as returns on its benchmark rise, returns on holding NewAmsterdam Pharma are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, NewAmsterdam Pharma is expected to outperform its benchmark. Additionally NewAmsterdam Pharma has an alpha of 0.0837, implying that it can generate a 0.0837 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   NewAmsterdam Pharma Price Density   
       Price  

Predictive Modules for NewAmsterdam Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NewAmsterdam Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NewAmsterdam Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
20.5826.0231.46
Details
Intrinsic
Valuation
LowRealHigh
15.8621.3026.74
Details
Naive
Forecast
LowNextHigh
23.4228.8634.30
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-7.0624.0927.20
Details

NewAmsterdam Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. NewAmsterdam Pharma is not an exception. The market had few large corrections towards the NewAmsterdam Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NewAmsterdam Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NewAmsterdam Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.08
β
Beta against Dow Jones-1.36
σ
Overall volatility
2.86
Ir
Information ratio -0.01

NewAmsterdam Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NewAmsterdam Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NewAmsterdam Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
NewAmsterdam Pharma generated a negative expected return over the last 90 days
NewAmsterdam Pharma has high historical volatility and very poor performance
NewAmsterdam Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 22.5 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 22.5 M.
NewAmsterdam Pharma generates negative cash flow from operations
NewAmsterdam Pharma has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: NewAmsterdam Expands Obicetrapib Trials Into Diabetes And Alzheimers As Losses Mount - simplywall.st

NewAmsterdam Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NewAmsterdam Stock often depends not only on the future outlook of the current and potential NewAmsterdam Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NewAmsterdam Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding114.4 M
Cash And Short Term Investments636.2 M

NewAmsterdam Pharma Fundamentals Growth

NewAmsterdam Stock prices reflect investors' perceptions of the future prospects and financial health of NewAmsterdam Pharma, and NewAmsterdam Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NewAmsterdam Stock performance.

About NewAmsterdam Pharma Performance

Evaluating NewAmsterdam Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NewAmsterdam Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NewAmsterdam Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.27)(0.28)
Return On Capital Employed(0.33)(0.35)
Return On Assets(0.26)(0.28)
Return On Equity(0.30)(0.31)

Things to note about NewAmsterdam Pharma performance evaluation

Checking the ongoing alerts about NewAmsterdam Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NewAmsterdam Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
NewAmsterdam Pharma generated a negative expected return over the last 90 days
NewAmsterdam Pharma has high historical volatility and very poor performance
NewAmsterdam Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 22.5 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 22.5 M.
NewAmsterdam Pharma generates negative cash flow from operations
NewAmsterdam Pharma has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: NewAmsterdam Expands Obicetrapib Trials Into Diabetes And Alzheimers As Losses Mount - simplywall.st
Evaluating NewAmsterdam Pharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate NewAmsterdam Pharma's stock performance include:
  • Analyzing NewAmsterdam Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NewAmsterdam Pharma's stock is overvalued or undervalued compared to its peers.
  • Examining NewAmsterdam Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating NewAmsterdam Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NewAmsterdam Pharma's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of NewAmsterdam Pharma's stock. These opinions can provide insight into NewAmsterdam Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating NewAmsterdam Pharma's stock performance is not an exact science, and many factors can impact NewAmsterdam Pharma's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.